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Background
DPD deficiency is the result of loss-of-function mutations
within the dihydropyrimidine dehydrogenase (DPD)
gene. The IVS14+1G>A variant is associated with DPD
deficiency as a result of a 165-bp deletion in the DPD
mRNA. A rare mutation, c.2846A>T, is characterized by
a change of the acidic aspartic acid to the aliphatic valine
with potential impairment of enzyme activity [1].
Scientific objectives
In this study, we describe the spectrum of toxicities of
fluoropyrimidines in patients carrying the IVS14+1G>A
and 2846A>T variants.
Technological approaches
Data were collected from 550 patients with gastrointest-
inal, breast, head-neck and pancreatic cancers. They were
evaluated for DPD genotype upon development of grade
≥2 non-hematological and ≥3 hematological toxicities
(CTCAE v.4) following standard fluoropyrimidine-
containing regimens in combination with other cytotoxic
agents and/or anti-EGFR and VEGF antibodies. DNA was
extracted from blood by the Qiamp DNA Blood Mini Kit
(Qiagen®) and IVS14+1G>A and 2846T>C DPD variants
were screened on a Real-Time Life Sciences® 7900 HT
platform. The study was approved by the local Ethics
Committee.
Results interpretation
A total of 27 IVS14+1GA, five 2846AT, one IVS14+1AA
and one 2846TT subjects were identified. Toxicities in all
subjects were G3/4 diarrhea (100%), G3/4 mucositis
(48%), febrile neutropenia (45%), G3/4 thrombocytopenia
(38%), G3/4 anemia (24%), G2/3 hand-foot syndrome
(14%), G3 dermatitis (7%) and G2/4 alopecia (7%). The
IVS14+1AA patient showed diarrhea G2, mucositis G3,
anemia G1, pistrinopenia G3, febrile neutropenia G4,
complete alopecia and Staphylococcus aureus sepsis. This
patient required 20 days of hospitalization and was mana-
ged with antibiotics, platelet transfusion, port removal,
G-CSF administration and parenteral nutrition. The
patient survived because she was given a reduced 5-FU
250 mg/sqm test dose without folates, while the 2846TT
patient deceased after the first cycle of FOLFOX4 treat-
ment because of a diarrhea G3, mucositis G4, febrile neu-
tropenia and piastrinopenia G4.
Outlook and expert recommendations
Patients carrying the deleterious IVS14+1G>A and
2846T>C variant alleles display severe toxicities which
are fatal in homozygous variant subjects. Although the
frequence of DPYD*2A allele is low, the screening for
DPD mutation is clinically relevant to avoid the severe
toxicities or death in patients treated with fluoropyrimi-
dine-containing regimens. This finding suggests the use-
fulness of pre-treatment screening of DPD in patients
candidates to fluoropyrimidine treatment.
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